The Filing Desk

Fortress Biotech

FBIO · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

FBIO · Last close · November 19, 2026
$1.77
Value Fortress Biotech yourself

Fortress Biotech's revenue rose 9.7% to $63 million in fiscal 2025. Its operating margin was −111.0%, up from −191.4% a year earlier. It paid out $1 million in dividends and buybacks. The diluted share count rose 34.2%.

Fortress Biotech, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 31, 2026 · 0001104659-26-037874 Updated
Revenue
$63M
9.7%
Operating margin
−111.0%
80.4 pts
Net income
$7M
 
Free cash flow
—
 
Return on capital
−323.7%
 
Market cap
$60M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-14.9254), so every year is on today's share basis. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Fortress Biotech does

Fortress Biotech is a drug company that licenses or buys the rights to medicines and drug candidates, often from universities and research hospitals, and develops them through a group of subsidiaries and partner companies it controls. Some of those companies are listed on their own, such as Journey Medical and Mustang Bio. Fortress aims to earn money from product sales, from the shares it holds in these companies, and from royalties and payments when it sells or licenses a drug to a larger company.

Its only revenue from selling medicines comes through Journey Medical, which markets prescription skin treatments in the United States, including Emrosi and Zilxi for rosacea, Amzeeq and Accutane for acne, and Qbrexza for heavy underarm sweating. Its other programs are still in development.

Fortress has also earned money by selling companies and rights. In May 2025 Sun Pharma bought its former subsidiary Checkpoint, and Fortress received $28.0 million and a royalty on sales of Checkpoint's skin-cancer drug. In January 2026 the FDA approved ZYCUBO, a copper treatment for children with Menkes disease developed by its subsidiary Cyprium, which then agreed to sell a related FDA priority review voucher for $205 million. At the end of 2025 Fortress and its companies had 78 full-time employees.

Its biggest risks, as it describes them

  • Most of its drug candidates are at an early stage and may never be approved or sold.
  • It has a history of losses and may need more money, which could dilute shareholders or force it to cut programs.
  • Sales of Journey's skin products could fall, including as they face generic competition.
  • Its heavy reliance on outside firms to develop, make and test its products, and on licenses for most of its technology.
  • Some of its executives also run its partner companies and control its direction, which could create conflicts of interest.
From Fortress Biotech's annual report on Form 10-K, filed March 31, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments306178815779
Debt incl. finance leases4392615852
Net debt (negative means net cash)−263−87−201−27
Net debt to EBITDA—————
Debt to equity0.4x2.2x2.7x2.5x1.1x
Interest coverage−12.3x−16.3x−9.3x−8.2x−7.0x
Current ratio3.4x1.8x1.4x1.3x2.5x
Quick ratio3.3x1.7x1.3x1.1x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Fortress Biotech's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $340,398 of Fortress Biotech shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 19, 2026Lindsay A Md RosenwaldPresident, CEO & Chairman, Director, 10% ownerBought17,456$1.86$32,440Form 4
Nov 19, 2026David JinChief Financial OfficerBought7,605$1.87$14,221Form 4
Nov 18, 2026Lindsay A Md RosenwaldPresident, CEO & Chairman, Director, 10% ownerBought54,776$1.90$104,233Form 4
Nov 18, 2026David JinChief Financial OfficerBought25,000$1.91$47,798Form 4
Nov 17, 2026Lindsay A Md RosenwaldPresident, CEO & Chairman, Director, 10% ownerBought64,491$1.80$115,910Form 4
Nov 17, 2026David JinChief Financial OfficerBought15,000$1.72$25,796Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 91 of 96 of 9
Rule of 40−140.2%−170.8%—
Altman Z''−17.96−21.04−12.29
Accruals ratio29.3%21.9%44.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailFailFail
Debt fell relative to assetsPassFailPass
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsPassPassPass
F-score4 of 91 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Fortress Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Fortress BiotechFY259.7%−111.0%—−323.7%—6
Enanta PharmaceuticalsFY26−3.6%−99.0%−67.9%———Compare
Nuvation BioFY25699.0%−338.7%−288.4%———Compare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———Compare
Journey MedicalFY2510.2%−13.2%—−22.4%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue16172737466976845863
Revenue growth1,809.6%4.6%55.9%36.3%24.5%50.9%10.1%11.6%−31.8%9.7%
Gross profit16142126313745623742
Research and development35488781641291351065712
Operating income−66−90−120−111−94−188−204−142−110−70
Net income−55−67−84−40−46−65−87−61−467
Diluted EPS (US$)−20.70−24.15−29.10−10.95−9.75−11.85−15.97−8.47−2.69−0.07
Diluted shares (millions)333455682128
Cash flow
Cash from operations−46−81−99−95−84−116−179−128−80−66
Capital expenditure617225300—
Free cash flow−52−82−106−97−86−121−182−128−80—
Dividends paid0000011111
Share buybacks0000000000
Acquisitions5500000000
Stock-based compensation12131513142023173329
Balance sheet at fiscal year end
Cash and short-term investments8813183137233306178815779
Debt incl. finance leases30688485524392615852
Total assets171246141226333396294168144186
Total liabilities88125121154136171244166146123
Shareholders' equity385322610010942222350
Margins and ratios
Gross margin95.2%78.8%77.2%71.2%68.0%53.4%59.4%72.9%63.8%66.9%
Operating margin−398.7%−520.7%−446.4%−302.5%−206.7%−274.1%−268.8%−168.4%−191.4%−111.0%
Net margin−334.3%−387.8%−313.0%−109.1%−102.0%−94.1%−114.3%−71.8%−79.8%10.8%
Free cash flow margin−316.6%−475.2%−394.1%−265.6%−187.7%−176.1%−240.4%−151.8%−139.0%—
Rule of 40 (growth + FCF margin)1,493.0%−470.6%−338.2%−229.4%−163.2%−125.2%−230.3%−140.2%−170.8%—
Return on capital−296.6%−173.0%−242.7%−423.3%—————−323.7%
Return on equity−115.6%−146.9%−309.2%−284.8%−73.5%−61.9%−115.1%−188.7%−203.2%18.8%
Return on assets−38.1%−32.1%−43.5%−21.8%−16.6%−17.7%−25.1%−26.3%−29.5%4.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Fortress Biotech's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Fortress Biotech.